PSC, or primary sclerosing cholangitis, is a chronic liver disease in which the bile ducts inside and outside the liver become inflamed and progressively scarred. Over time, this scarring narrows the ducts, blocks the flow of bile, and damages the liver itself. The median transplant-free survival after diagnosis ranges from 15 to 21 years, though many people live longer, and the course varies widely from person to person.
How PSC Damages the Bile Ducts
Bile ducts are the small tubes that carry bile from the liver to the small intestine, where it helps digest fats. In PSC, the immune system triggers ongoing inflammation of the cells lining these ducts. Researchers believe this process starts after exposure to an unknown environmental trigger in people who are genetically susceptible, but no one has identified a single cause.
The inflammation sets off a chain reaction. Immune cells release signaling molecules that attract more inflammation and promote scar tissue growth around the ducts. Toxic bile leaks between the damaged lining cells, fueling even more scarring. The scar tissue forms in a distinctive ring pattern around each duct, sometimes called “onion skin” fibrosis because the layers wrap concentrically like the layers of an onion. As scarring thickens, it squeezes the tiny blood vessels that supply oxygen to the duct walls, which starves the tissue and accelerates further damage. The ducts stiffen, narrow, and eventually block bile from draining properly.
Symptoms and How They Progress
Most people with PSC have no symptoms at the time of diagnosis. In population-based studies, roughly 57% of patients are first identified through abnormal liver blood tests found during routine lab work. When symptoms do appear, they tend to develop slowly.
Fatigue is usually the first thing people notice, followed by persistent itching (pruritus) that can range from mild to severe. Some people develop abdominal pain, particularly in the upper right side. Diarrhea and intermittent fevers can also occur, especially during flare-ups of bile duct infection (cholangitis). Jaundice, a yellowing of the skin and eyes, tends to appear later and signals that the disease has advanced significantly. As liver damage accumulates over years, complications like fluid buildup in the abdomen, enlarged veins in the esophagus, and cognitive changes from toxin buildup can develop.
The Link to Inflammatory Bowel Disease
PSC has an unusually strong connection to inflammatory bowel disease (IBD), particularly ulcerative colitis. About 60 to 80% of people with PSC also have some form of IBD. The relationship also works in the other direction, though less dramatically: in a large multinational study of over 51,000 IBD patients, about 1.4% of those with ulcerative colitis had PSC, compared to just 0.13% of those with Crohn’s disease.
The two conditions don’t always flare at the same time, and treating one doesn’t necessarily control the other. If you’re diagnosed with PSC, your doctor will typically check for IBD even if you have no gut symptoms, and vice versa. The colon inflammation in PSC-related IBD tends to be mild and widespread, which can make it easy to miss without a colonoscopy.
How PSC Is Diagnosed
The hallmark of PSC shows up on imaging. A specialized MRI called magnetic resonance cholangiopancreatography (MRCP) is the primary tool used to visualize the bile ducts without any invasive procedure. The scarred, narrowed ducts alternate with slightly dilated segments, creating a characteristic “beads on a string” appearance on the scan. An older technique called ERCP, which threads a small scope through the mouth and into the bile ducts, can produce similar images and remains the gold standard, but MRCP is preferred for initial diagnosis because it carries no procedural risk.
A liver biopsy is sometimes performed to help confirm the diagnosis or to stage how much damage has occurred, but it isn’t always necessary if the imaging findings are clear.
Cancer Risk in PSC
One of the most serious aspects of PSC is the elevated risk of certain cancers. Bile duct cancer (cholangiocarcinoma) is the greatest concern. The annual incidence in PSC patients is estimated at 0.5% to 1.5% per year, and the lifetime risk reaches roughly 20%. This is dramatically higher than in the general population, and it can develop at any stage of the disease, not just in advanced cases.
Gallbladder cancer also occurs more frequently, with a lifetime incidence estimated between 3% and 14%. Liver cancer (hepatocellular carcinoma) is less common, with a lifetime risk of about 0.3% to 2.8%. People with both PSC and ulcerative colitis also face an increased risk of colorectal cancer, which is why regular colonoscopy surveillance is a routine part of managing the disease.
Treatment Options
There is currently no medication proven to slow or stop PSC progression. The most studied drug, ursodeoxycholic acid (a synthetic bile acid), improves liver blood test numbers but has consistently failed to show a real benefit in preventing death, transplant, or disease progression across multiple clinical trials. At higher doses, it actually increased the risk of worse outcomes, leading guidelines to recommend against its use at those levels. Some doctors still prescribe it at moderate doses based on the biochemical improvement it provides, but its role remains controversial.
Treatment instead focuses on managing symptoms and complications. Itching can be addressed with medications that reduce bile acid levels in the blood. Bacterial infections of the bile ducts (cholangitis episodes) are treated with antibiotics. When a major narrowing, called a dominant stricture, develops in one of the larger bile ducts, it can be opened using a balloon threaded through an endoscope. Dominant strictures occur in up to 60% of PSC patients and can cause sudden worsening of symptoms. Studies suggest that balloon dilation alone is generally sufficient to restore bile flow, without the need for placing a permanent stent.
Liver Transplantation
For people whose disease progresses to liver failure or who develop recurrent, debilitating cholangitis that doesn’t respond to other treatments, liver transplantation is the only definitive option. In one multicenter study, the most common reasons for transplant were chronic liver failure (about 38% of cases), recurrent cholangitis (30%), severe itching unresponsive to treatment (11%), and cognitive changes from liver-related toxin buildup (11%).
Patients in that study had an average MELD score of 23 at the time of transplant. The MELD score is a number from 6 to 40 that estimates the severity of liver disease: higher numbers reflect more urgent need. Outcomes after transplant are generally good compared to many other liver diseases, though PSC can recur in the new liver in a minority of cases.
What Research Is Exploring
One area generating interest is oral vancomycin, a non-absorbed antibiotic that stays in the gut. Early reports have linked it to improvements in liver blood tests, clinical symptoms, and even IBD-related symptoms in PSC patients. A phase 2 clinical trial is currently underway in Italy to more rigorously test its effectiveness. The drug is generally well tolerated, with occasional nausea, bloating, or rash, though rare cases of liver injury have been reported. Results from this and similar trials will help clarify whether targeting gut bacteria could meaningfully change the course of PSC.